MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG and M.A. DIMOPOULOS. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. London: Nature Publishing Group, 2017, vol. 31, No 1, p. 115-122. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/leu.2016.186. |
Other formats:
BibTeX
LaTeX
RIS
@article{1369191, author = {Moreau, P. and Joshua, D. and Chng, W.andJ. and Palumbo, A. and Goldschmidt, H. and Hájek, R. and Facon, T. and Ludwig, H. and Pour, Luděk and Niesvizky, R. and Oriol, A. and Rosiñol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and GoranovaandMarinova, V. and Gillenwater, H.H. and Mohamed, N. and Aggarwal, S. and Feng, S. and Dimopoulos, M.A.}, article_location = {London}, article_number = {1}, doi = {http://dx.doi.org/10.1038/leu.2016.186}, keywords = {2ND-GENERATION PROTEASOME INHIBITOR; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; RETREATMENT}, language = {eng}, issn = {0887-6924}, journal = {Leukemia}, title = {Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study}, url = {http://dx.doi.org/10.1038/leu.2016.186}, volume = {31}, year = {2017} }
TY - JOUR ID - 1369191 AU - Moreau, P. - Joshua, D. - Chng, W.-J. - Palumbo, A. - Goldschmidt, H. - Hájek, R. - Facon, T. - Ludwig, H. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosiñol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Gillenwater, H.H. - Mohamed, N. - Aggarwal, S. - Feng, S. - Dimopoulos, M.A. PY - 2017 TI - Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study JF - Leukemia VL - 31 IS - 1 SP - 115-122 EP - 115-122 PB - Nature Publishing Group SN - 08876924 KW - 2ND-GENERATION PROTEASOME INHIBITOR KW - STEM-CELL TRANSPLANTATION KW - LENALIDOMIDE MAINTENANCE KW - RETREATMENT UR - http://dx.doi.org/10.1038/leu.2016.186 L2 - http://dx.doi.org/10.1038/leu.2016.186 N2 - The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with greater than or equal to2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (greater than or equal to2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide. ER -
MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG and M.A. DIMOPOULOS. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. \textit{Leukemia}. London: Nature Publishing Group, 2017, vol.~31, No~1, p.~115-122. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/leu.2016.186.
|